Cevec and Biolamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies
![](/46/pdcnewsitem/03/77/03/Cevec.png)
First commercial CAPGo-derived laminin, LN-521, expected to be globally available in 2016.
CEVEC Pharmaceuticals (CEVEC) and BioLamina have announced a strategic collaboration for the commercial production of research grade and clinical grade laminins for ex vivo cell culture applications using CEVEC’s proprietary CAPGo technology, which is optimal for the production of these otherwise difficult to produce recombinant glycoproteins. Financial details of this agreement were not disclosed.
Under the terms of the agreement, CEVEC will provide its expertise in process development, as well as its competence in GMP production, in collaboration with its joint venture partner GenIbet, of selected laminins based on the company’s proprietary CAPGo technology. This joined competence embraces cell line and process development, GMP cell banking and GMP production including fill & finish. CEVEC retains the rights to develop laminins for therapeutic use and grants BioLamina an exclusive license for the commercialization of CAPGo based laminins patented by BioLamina for ex vivo cell culture therapies. The first laminin, Laminin-521, which is used to proliferate stem cells without causing genomic abnormalities, will be launched in 2016.
BioLamina focuses on research and development, to understand how laminins can be used to deplete technical problems associated in primary cell culture as well as on global sales and marketing of the commercially produced and finished products through its direct sales force and network of distributors. In this long-term strategic cooperation, BioLamina plans to initially add up to six new variants of laminins to its leading portfolio of recombinant laminins to enable cell culture of an accelerating range of human cell types with increased reliability and quality.
“The agreement with BioLamina is again an endorsement of our CAPGo expression platform and represents a further milestone in our strategy to continuously open up new areas for our technology. It also marks the transition of the Company towards a “Center of Expertise” in tailor-made glycosylation of recombinant proteins,” commented Frank Ubags, CEO of CEVEC Pharmaceuticals. “Over recent months, we successfully positioned CAPGo as the technology of choice in high growth areas including difficult to express glycoproteins for ex vivo cell culture therapies as well as therapeutically relevant plasma and serum proteins. Today, manufacturing is still a limiting factor for the therapeutic use of recombinant glycoproteins. Given the superior pharmacokinetic profiles shown by CAPGo-derived glycoproteins, we are anticipating drug development companies to switch from CHO-Technologies and HEK 293-Technologies to our CAPGo technology.”
“CEVEC’s CAPGo technology and their expertise in cell line development, process development and manufacturing is crucial for us to meet the increasing demand of LN-521 as well as changing the laminin production process to meet regulatory guidelines for clinical use in advanced cell therapies,” said Kristian Tryggvason, CEO of BioLamina AB. “The highly efficient GMP production capabilities as well as the superior function of the proteins expressed with the CAPGo platform allows us to maintain BioLamina’s high quality standards for our ex vivo cell culture laminin product portfolio.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance